GlassScriptPhysician profile
Thomas B Redens
NPI 1134144926
$4,056.87
in general payments reported to CMS, 2019-2025
11 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $118 · 2021: $375 · 2022: $492 · 2023: $1,001 · 2024: $825 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,022.66 | 2019-2025 | Clareon, Argos, Clareon Panoptix Pro |
| Sight Sciences, INC. | $399.03 | 2023-2025 | Omni Surgical System |
| Amgen INC. | $205.78 | 2024-2025 | Uplizna, Tepezza |
| Glaukos Corporation | $140.15 | 2022 | |
| Abbvie INC. | $93.73 | 2023 | |
| Horizon Therapeutics Plc | $64.94 | 2021 | |
| Apellis Pharmaceuticals, INC. | $53.91 | 2024-2025 | Syfovre |
| Genentech USA, INC. | $29.60 | 2025 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $17.42 | 2020 | |
| Bausch & Lomb Americas INC. | $15.69 | 2022 | |
| Kala Pharmaceuticals, INC. | $13.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Redens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.